Hong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hong Li has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Rui Tang
State Key Laboratory of Complex Severe and Rare Diseases, Allergy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
10 shared publicationsXiaohong Lyu
State Key Laboratory of Complex Severe and Rare Diseases, Allergy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 shared publicationsLiping Zhu
Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
3 shared publications- Jinlyu Sun
Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
2 shared publications Li-Ping Zhu
Allergy Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China
2 shared publicationsQing Wang
Allergy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
2 shared publications
Latest Publications
- Open Access
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (10) , 1215-1223
Genetic Polymorphisms of GP1BA, PEAR1, and PAI-1 may be Associated with Serum sIgE and Blood Eosinophil Levels in Chinese Patients with Allergic Diseases
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. Objective: This study aims to investigate the relationship between the serum specific Immunoglobulin E (sIgE), blood eosinophil, and the polymorphisms of glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and plasminogen activator inhibitor 1 gene (PAI-1) rs1799762. Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 283 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group. Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa =1, p < 0.001). The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms did not show different distribution between allergy patients and healthy individuals. Concerning allergy patients, the CT (n=33) genotype of GP1BA rs6065 had higher blood eosinophil level than the CC (n=250) genotype (0.59, IQR 0.32-0.72 vs 0.31, IQR 0.15-0.61, *109/L, p =0.005). The serum sIgE of AA (n=46) genotype of PEAR1 rs12041331 was lower (median 3.7, interquartile quartiles (IQR) 0.2-16.8, kU/L) than the GA (n=136) and GG (n=101) genotypes (GA median 16.3, IQR 3.1-46.3, kU/L, p = 0.002; GG median 12.9, IQR 3.0-46.9, kU/L, p =0.003). The GA genotypes of PEAR1 rs12041331were with higher blood eosinophil levels (median 0.42, IQR 0.17-0.74 *109/L) than the AA genotype (median 0.25, IQR 0.15-0.41*109/L, p =0.012). The sIgE of the 5G5G (n=44) genotype of PAI-1 rs1799762 was lower (median 5.0, IQR 0.1-22.8, kU/L) than the 4G5G (n=144) (median 17.3, IQR 3.7-46.0, kU/L, p = 0.012). Conclusion: The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of serum sIgE or blood eosinophil in Chinese allergic disease patients.
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (10) , 1215-1223
Open AccessGenetic Polymorphisms of GP1BA, PEAR1, and PAI-1 may be Associated with Serum sIgE and Blood Eosinophil Levels in Chinese Patients with Allergic Diseases
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. Objective: This study aims to investigate the relationship between the serum specific Immunoglobulin E (sIgE), blood eosinophil, and the polymorphisms of glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and plasminogen activator inhibitor 1 gene (PAI-1) rs1799762. Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 283 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group. Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa =1, p < 0.001). The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms did not show different distribution between allergy patients and healthy individuals. Concerning allergy patients, the CT (n=33) genotype of GP1BA rs6065 had higher blood eosinophil level than the CC (n=250) genotype (0.59, IQR 0.32-0.72 vs 0.31, IQR 0.15-0.61, *109/L, p =0.005). The serum sIgE of AA (n=46) genotype of PEAR1 rs12041331 was lower (median 3.7, interquartile quartiles (IQR) 0.2-16.8, kU/L) than the GA (n=136) and GG (n=101) genotypes (GA median 16.3, IQR 3.1-46.3, kU/L, p = 0.002; GG median 12.9, IQR 3.0-46.9, kU/L, p =0.003). The GA genotypes of PEAR1 rs12041331were with higher blood eosinophil levels (median 0.42, IQR 0.17-0.74 *109/L) than the AA genotype (median 0.25, IQR 0.15-0.41*109/L, p =0.012). The sIgE of the 5G5G (n=44) genotype of PAI-1 rs1799762 was lower (median 5.0, IQR 0.1-22.8, kU/L) than the 4G5G (n=144) (median 17.3, IQR 3.7-46.0, kU/L, p = 0.012). Conclusion: The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of serum sIgE or blood eosinophil in Chinese allergic disease patients.
- Open Access
- 29 March 2024
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 72 (14) , 8189-8199
Identification, Characterization, Cloning, and Cross-Reactivity of Zan b 2, a Novel Pepper Allergen of 11S Legumin
Protein from Sichuan peppers can elicit mild to severe allergic reactions. However, little is known about their allergenic proteins. We aimed to isolate, identify, clone, and characterize Sichuan pepper allergens and to determine its allergenicity and cross-reactivities. Sichuan pepper seed proteins were extracted and then analyzed by SDS-PAGE. Western blotting was performed with sera from Sichuan pepper-allergic individuals. Proteins of interest were purified using hydrophobic interaction chromatography and gel filtration and further analyzed by analytical ultracentrifugation, circular dichroism spectroscopy, and mass spectrometry (MS). Their coding region was amplified in the genome. IgE reactivity and cross-reactivity of allergens were evaluated by dot blot, enzyme-linked immunosorbent assay (ELISA), and competitive ELISA. Western blot showed IgE binding to a 55 kDa protein. This protein was homologous to the citrus proteins and has high stability and a sheet structure. Four DNA sequences were cloned. Six patients' sera (60%) showed specific IgE reactivity to this purified 11S protein, which was proved to have cross-reactivation with extracts of cashew nuts, pistachios, and citrus seeds. A novel allergen in Sichuan pepper seeds, Zan b 2, which belongs to the 11S globulin family, was isolated and identified. Its cross-reactivity with cashew nuts, pistachios, and citrus seeds was demonstrated.
- 29 March 2024
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 72 (14) , 8189-8199
Open AccessIdentification, Characterization, Cloning, and Cross-Reactivity of Zan b 2, a Novel Pepper Allergen of 11S Legumin
Protein from Sichuan peppers can elicit mild to severe allergic reactions. However, little is known about their allergenic proteins. We aimed to isolate, identify, clone, and characterize Sichuan pepper allergens and to determine its allergenicity and cross-reactivities. Sichuan pepper seed proteins were extracted and then analyzed by SDS-PAGE. Western blotting was performed with sera from Sichuan pepper-allergic individuals. Proteins of interest were purified using hydrophobic interaction chromatography and gel filtration and further analyzed by analytical ultracentrifugation, circular dichroism spectroscopy, and mass spectrometry (MS). Their coding region was amplified in the genome. IgE reactivity and cross-reactivity of allergens were evaluated by dot blot, enzyme-linked immunosorbent assay (ELISA), and competitive ELISA. Western blot showed IgE binding to a 55 kDa protein. This protein was homologous to the citrus proteins and has high stability and a sheet structure. Four DNA sequences were cloned. Six patients' sera (60%) showed specific IgE reactivity to this purified 11S protein, which was proved to have cross-reactivation with extracts of cashew nuts, pistachios, and citrus seeds. A novel allergen in Sichuan pepper seeds, Zan b 2, which belongs to the 11S globulin family, was isolated and identified. Its cross-reactivity with cashew nuts, pistachios, and citrus seeds was demonstrated.
- Open Access
- 28 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1363034
Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever
Background: Hay fever, characterized by seasonal allergic reactions, poses a significant health challenge. Existing therapies encompass standard drug regimens, biological agents, and specific immunotherapy. This study aims to assess and compare the effectiveness of anti-IgE (omalizumab), medication therapy, and subcutaneous immunotherapy (SCIT) for hay fever.Methods: Conducted as a retrospective cohort study, this research involved 98 outpatient hay fever patients who underwent routine medication, omalizumab treatment, or SCIT before the onset of the spring pollen season. A follow-up was performed one month after the start of the pollen season. The comprehensive symptoms and drug scores were used to evaluate patients with different intervention methods, facilitating a comparative analysis of therapeutic outcomes.Results: Compared with before treatment, the symptoms of patients treated with the three methods were all significantly relieved, and the medication score were significantly reduced. Patients treated with omalizumab demonstrated higher symptoms and medication scores than SCIT group before treatment, but similar scores after treatment, which were both lower than medicine treatment group. After treatment with omalizumab or SCIT, patients in both groups had significantly lower medication scores than the medication group and were close to no longer using medication for symptom relief. The mountain juniper-sIgE was significantly higher after treatment than before treatment in both medicine treatment group and omalizumab treatment group.Conclusion: Omalizumab and SCIT offer superior effects than medication therapy in hay fever patients.
- 28 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1363034
Open AccessComparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever
Background: Hay fever, characterized by seasonal allergic reactions, poses a significant health challenge. Existing therapies encompass standard drug regimens, biological agents, and specific immunotherapy. This study aims to assess and compare the effectiveness of anti-IgE (omalizumab), medication therapy, and subcutaneous immunotherapy (SCIT) for hay fever.Methods: Conducted as a retrospective cohort study, this research involved 98 outpatient hay fever patients who underwent routine medication, omalizumab treatment, or SCIT before the onset of the spring pollen season. A follow-up was performed one month after the start of the pollen season. The comprehensive symptoms and drug scores were used to evaluate patients with different intervention methods, facilitating a comparative analysis of therapeutic outcomes.Results: Compared with before treatment, the symptoms of patients treated with the three methods were all significantly relieved, and the medication score were significantly reduced. Patients treated with omalizumab demonstrated higher symptoms and medication scores than SCIT group before treatment, but similar scores after treatment, which were both lower than medicine treatment group. After treatment with omalizumab or SCIT, patients in both groups had significantly lower medication scores than the medication group and were close to no longer using medication for symptom relief. The mountain juniper-sIgE was significantly higher after treatment than before treatment in both medicine treatment group and omalizumab treatment group.Conclusion: Omalizumab and SCIT offer superior effects than medication therapy in hay fever patients.
- Open Access
- 30 June 2023
- Published by Chinese Medical Sciences Journal in Chinese Medical Sciences Journal
- Vol. 38 (2) , 159-162
Dupilumab for Treatment of Food-Dependent, Exercise-Induced Anaphylaxis: Report of One Case
Food-dependent, exercise-induced anaphylaxis (FDEIA) is a potentially life-threatening disorder that often occurs with exercise, and patients typically have eaten a specific food within hours before disease onset. This disease is exceedingly rare, with a prevalence of 0.02%. No well-recognized prevention or treatment strategy has been available for FDEIA except avoiding triggers strictly. Here we report an 11-year-old boy with a history of recurrent anaphylaxis of unknown etiology more than 10 times within two years. As the anaphylactic symptoms had not been controlled after traditional treatments, the patient was given subcutaneous injection of dupilumab seven times within 33 weeks. During dupilumab treatments, the patient was exposed to culprit mushrooms plus exercises at least twice a month but without notable anaphylaxis. Thus, Dupilumab may improve the allergic reactions in FDEIA patients.
- 30 June 2023
- Published by Chinese Medical Sciences Journal in Chinese Medical Sciences Journal
- Vol. 38 (2) , 159-162
Open AccessDupilumab for Treatment of Food-Dependent, Exercise-Induced Anaphylaxis: Report of One Case
Food-dependent, exercise-induced anaphylaxis (FDEIA) is a potentially life-threatening disorder that often occurs with exercise, and patients typically have eaten a specific food within hours before disease onset. This disease is exceedingly rare, with a prevalence of 0.02%. No well-recognized prevention or treatment strategy has been available for FDEIA except avoiding triggers strictly. Here we report an 11-year-old boy with a history of recurrent anaphylaxis of unknown etiology more than 10 times within two years. As the anaphylactic symptoms had not been controlled after traditional treatments, the patient was given subcutaneous injection of dupilumab seven times within 33 weeks. During dupilumab treatments, the patient was exposed to culprit mushrooms plus exercises at least twice a month but without notable anaphylaxis. Thus, Dupilumab may improve the allergic reactions in FDEIA patients.
- Open Access
- 24 February 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1139813
The 4G/5G polymorphism of plasminogen activator inhibitor type 1 is a predictor of allergic cough
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. This study aims to investigate the relationship between the genetic susceptibility of Chinese patients with allergy disorders and the polymorphisms of plasminogen activator inhibitor 1 gene (PAI-1) rs1799762, cysteinyl leukotriene receptor 1 gene (CYSLTR1) rs320995, gasdermin B gene (GSDMB) rs7216389, glycoprotein IIIa gene (GPIIIa) rs5918, glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and tumor necrosis factor alpha gene (TNF-α) rs1800629.Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 286 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group.Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa = 1, p < .001). Only the distribution of PAI-1 rs1799762 was different between patients with allergic cough and healthy people (χ2 = 7.48, p = .0238). With regard to cough patients, the 4G4G and 5G5G genotypes were more frequent (allergic cough vs. healthy individuals: 4G4G 57.9% vs. 26.7%; 5G5G 20.0% vs. 13.3%), but the 4G5G genotype was more frequent in healthy people (allergic cough vs. healthy individuals: 45.7% vs. 60.0%). The CYSLTR1 rs320995, GSDMB rs7216389, GPIIIa rs5918, GP1BA rs6065, PEAR1 rs12041331, and TNF-α rs1800629 polymorphisms, however, did not show any of such relationships.Conclusion: The PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of Chinese allergic disease patients with cough performance.
- 24 February 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1139813
Open AccessThe 4G/5G polymorphism of plasminogen activator inhibitor type 1 is a predictor of allergic cough
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. This study aims to investigate the relationship between the genetic susceptibility of Chinese patients with allergy disorders and the polymorphisms of plasminogen activator inhibitor 1 gene (PAI-1) rs1799762, cysteinyl leukotriene receptor 1 gene (CYSLTR1) rs320995, gasdermin B gene (GSDMB) rs7216389, glycoprotein IIIa gene (GPIIIa) rs5918, glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and tumor necrosis factor alpha gene (TNF-α) rs1800629.Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 286 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group.Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa = 1, p < .001). Only the distribution of PAI-1 rs1799762 was different between patients with allergic cough and healthy people (χ2 = 7.48, p = .0238). With regard to cough patients, the 4G4G and 5G5G genotypes were more frequent (allergic cough vs. healthy individuals: 4G4G 57.9% vs. 26.7%; 5G5G 20.0% vs. 13.3%), but the 4G5G genotype was more frequent in healthy people (allergic cough vs. healthy individuals: 45.7% vs. 60.0%). The CYSLTR1 rs320995, GSDMB rs7216389, GPIIIa rs5918, GP1BA rs6065, PEAR1 rs12041331, and TNF-α rs1800629 polymorphisms, however, did not show any of such relationships.Conclusion: The PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of Chinese allergic disease patients with cough performance.
- Open Access
- 4 January 2023
- Published by Wiley
Dupilumab for treatment of food-dependent, exercise-induced anaphylaxis
Dupilumab for treatment of food-dependent, exercise-induced anaphylaxisLiping Zhu#, MB, Rui Tang#, MD, Qing Wang, BSN, Hong Li *, MDAllergy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.* Correspondence: Hong Li, E-mail: lihong@pumch.cn# These authors contributed equally to this workClinical Implications: This case provides evidence of treatment with dupilumab which improve the severity of allergic reactions in a patient with food-dependent, exercise-induced anaphylaxis.TO THE EDITOR,Food-dependent, exercise-induced anaphylaxis (FDEIA) is a potentially life-threatening disorder that often occurs with exercise, and with a history of eating culprit foods within a few hours before onset, but eating or exercise alone does not induce symptoms.1This disease is exceedingly rare with a prevalence was approximately 0.02% .2 Food allergens can stimulate mast cells to release inflammatory mediators like histamine and cytokines such as IL-4 and IL-13 after entering the body, increase intestinal permeability by enhancing IL-4Ra signaling, and enhance sensitivity to food allergens.3 Therefore, blocking IL-4 and IL-13 signaling pathways may reduce the symptoms of anaphylaxis.Dupilumab is a monoclonal antibody that inhibits IL-4 and IL-13 signaling by specifically binding to the IL-4Rα subunit of the IL-4 and IL-13 receptor complex. It has been studied for the treatment of atopic dermatitis, uncontrolled asthma, severe chronic sinusitis with nasal polyps, and eosinophilic esophagitis.4 A case reported that a 23-year-old female patient with severe asthma and unexplained severe allergic reactions which is not related to exercise. After being treated with dupilumab for asthma in two doses, no serious anaphylaxis requiring epinephrine occurred within the next 2 years.5But there has been no published report to clarify the clinical implication of treatment for anaphylaxis with dupilumab, especially for FDEIA which is a rare disorder.CASE REPORTGeneral informationWe present an 11-year-old boy with a history of recurrent anaphylaxis, asthma, allergic rhinitis, and allergic conjunctivitis due to cat, mites, fungus sensitization, and attacks of anaphylaxis related to the triggers of activities combined with uncertain foods. In June 2019, when the patient was exercising after ingesting common foods for around 2 hours, he developed anaphylaxis demonstrating systemic wheals itching, facial edema, eyelid redness and swelling, nasal congestion, cough, chest tightness, dyspnea, lip cyanosis, wheezing. The child experienced more than 10 episodes of anaphylaxis for 2 years, and 2 times went to the hospital for emergency treatment. His family felt that the episodes were unrelated to the food type at the previous visits. The patient’s asthma (CSMS, 2.33), allergic rhinitis (ACT score, 20) allergic conjunctivitis were controlled after treatment with Ventolin and Budesonide Formoterol Powder for Inhalation, Cetirizine, and fluticasone propionate nasal spray. He had been given dust mite sublingual drops for allergen immunotherapy (AIT) for more than half a year. But the anaphylaxis was not improved after the traditional treatments including the above medications use, AIT, and allergens avoidance.Specific IgE (ImmunoCAP) showed Alternaria alternata (30.43 KUA/L), cat dander (14.9 KUA/L), and Dermatophagoides farinae (15.4 KUA/L). Total IgE: 621.0 KU/L. The acetylcholine bronchial provocation test was positive: FEV1 decreased by 37%, PEF decreased by 27%, and PD20FEV1:0.0961 mg. Pulmonary function: FEV1 (L), 1.77; FEV1predicted (%), 78.4%; FEV1/FVC, 82.07%; FEV1/FVC predicted (%), 97.1%.Diagnosis and treatmentDue to unknown etiology, the patient was given the subcutaneous injection of dupilumab 7 times for a period of 33 weeks. Dupilumab was administered 300 mg subcutaneously every 4 weeks for the first 14 weeks and then changed to 300 mg every 6-7 weeks for the next 19 weeks due to symptom improvement. During the follow-up period of dupilumab treatment, skin prick tests (SPT) were performed on the foods of ostrea gigas thunberg, scallops, soybeans, corn, whole grains, and raw/cooked peanuts based on the patient’s parent-reported medical history and associated food diary, and all results were negative. Of these, ostrea gigas thunberg and scallops were previously considered the most associated with patient morbidity. After the recommendation to avoid these two foods, the symptoms continued to recur, so the possibility of these food triggers was tentatively ruled out. At the 7th follow-up visit of the patient on Dupilumab treatment, SPT results were positive for Morchella esculenta, Russula vinosa Lindblad, and Pleurotus eryngii which were associated with the patient’s history. And we found the patient had consumed these mushrooms before several attacks, but never felt discomfort in the past when only mushrooms were consumed without exercise. The patient was advised to avoid these mushrooms and to stop dupilumab treatment simultaneously, after which he did not have any episodes of anaphylaxis. Based on positive SPT results, the patient’s attack history, and the efficacy of avoiding mushrooms, the patient was diagnosed with FDEIA, and the mushroom was considered as the causative food.EfficacyDuring dupilumab treatments, the patient had experienced 2 times of mild allergic reactions, such as itchy skin, eyelid edema, or itching throat with the trigger of mushroom plus exercise (exposures for mushrooms plus exercise about at least twice a month), but no anaphylaxis within this time, and after stopping dupilumab and avoiding mushrooms (Figure 1). The diagnosis standard of anaphylaxis is based on the WAO guideline.6 The patient returned to normal exercise (running 1-2 km, soccer, etc.) with an improvement in quality of life and no adverse reactions occurred.Total IgE and specific IgE decreased significantly...
- 4 January 2023
- Published by Wiley
Open AccessDupilumab for treatment of food-dependent, exercise-induced anaphylaxis
Dupilumab for treatment of food-dependent, exercise-induced anaphylaxisLiping Zhu#, MB, Rui Tang#, MD, Qing Wang, BSN, Hong Li *, MDAllergy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.* Correspondence: Hong Li, E-mail: lihong@pumch.cn# These authors contributed equally to this workClinical Implications: This case provides evidence of treatment with dupilumab which improve the severity of allergic reactions in a patient with food-dependent, exercise-induced anaphylaxis.TO THE EDITOR,Food-dependent, exercise-induced anaphylaxis (FDEIA) is a potentially life-threatening disorder that often occurs with exercise, and with a history of eating culprit foods within a few hours before onset, but eating or exercise alone does not induce symptoms.1This disease is exceedingly rare with a prevalence was approximately 0.02% .2 Food allergens can stimulate mast cells to release inflammatory mediators like histamine and cytokines such as IL-4 and IL-13 after entering the body, increase intestinal permeability by enhancing IL-4Ra signaling, and enhance sensitivity to food allergens.3 Therefore, blocking IL-4 and IL-13 signaling pathways may reduce the symptoms of anaphylaxis.Dupilumab is a monoclonal antibody that inhibits IL-4 and IL-13 signaling by specifically binding to the IL-4Rα subunit of the IL-4 and IL-13 receptor complex. It has been studied for the treatment of atopic dermatitis, uncontrolled asthma, severe chronic sinusitis with nasal polyps, and eosinophilic esophagitis.4 A case reported that a 23-year-old female patient with severe asthma and unexplained severe allergic reactions which is not related to exercise. After being treated with dupilumab for asthma in two doses, no serious anaphylaxis requiring epinephrine occurred within the next 2 years.5But there has been no published report to clarify the clinical implication of treatment for anaphylaxis with dupilumab, especially for FDEIA which is a rare disorder.CASE REPORTGeneral informationWe present an 11-year-old boy with a history of recurrent anaphylaxis, asthma, allergic rhinitis, and allergic conjunctivitis due to cat, mites, fungus sensitization, and attacks of anaphylaxis related to the triggers of activities combined with uncertain foods. In June 2019, when the patient was exercising after ingesting common foods for around 2 hours, he developed anaphylaxis demonstrating systemic wheals itching, facial edema, eyelid redness and swelling, nasal congestion, cough, chest tightness, dyspnea, lip cyanosis, wheezing. The child experienced more than 10 episodes of anaphylaxis for 2 years, and 2 times went to the hospital for emergency treatment. His family felt that the episodes were unrelated to the food type at the previous visits. The patient’s asthma (CSMS, 2.33), allergic rhinitis (ACT score, 20) allergic conjunctivitis were controlled after treatment with Ventolin and Budesonide Formoterol Powder for Inhalation, Cetirizine, and fluticasone propionate nasal spray. He had been given dust mite sublingual drops for allergen immunotherapy (AIT) for more than half a year. But the anaphylaxis was not improved after the traditional treatments including the above medications use, AIT, and allergens avoidance.Specific IgE (ImmunoCAP) showed Alternaria alternata (30.43 KUA/L), cat dander (14.9 KUA/L), and Dermatophagoides farinae (15.4 KUA/L). Total IgE: 621.0 KU/L. The acetylcholine bronchial provocation test was positive: FEV1 decreased by 37%, PEF decreased by 27%, and PD20FEV1:0.0961 mg. Pulmonary function: FEV1 (L), 1.77; FEV1predicted (%), 78.4%; FEV1/FVC, 82.07%; FEV1/FVC predicted (%), 97.1%.Diagnosis and treatmentDue to unknown etiology, the patient was given the subcutaneous injection of dupilumab 7 times for a period of 33 weeks. Dupilumab was administered 300 mg subcutaneously every 4 weeks for the first 14 weeks and then changed to 300 mg every 6-7 weeks for the next 19 weeks due to symptom improvement. During the follow-up period of dupilumab treatment, skin prick tests (SPT) were performed on the foods of ostrea gigas thunberg, scallops, soybeans, corn, whole grains, and raw/cooked peanuts based on the patient’s parent-reported medical history and associated food diary, and all results were negative. Of these, ostrea gigas thunberg and scallops were previously considered the most associated with patient morbidity. After the recommendation to avoid these two foods, the symptoms continued to recur, so the possibility of these food triggers was tentatively ruled out. At the 7th follow-up visit of the patient on Dupilumab treatment, SPT results were positive for Morchella esculenta, Russula vinosa Lindblad, and Pleurotus eryngii which were associated with the patient’s history. And we found the patient had consumed these mushrooms before several attacks, but never felt discomfort in the past when only mushrooms were consumed without exercise. The patient was advised to avoid these mushrooms and to stop dupilumab treatment simultaneously, after which he did not have any episodes of anaphylaxis. Based on positive SPT results, the patient’s attack history, and the efficacy of avoiding mushrooms, the patient was diagnosed with FDEIA, and the mushroom was considered as the causative food.EfficacyDuring dupilumab treatments, the patient had experienced 2 times of mild allergic reactions, such as itchy skin, eyelid edema, or itching throat with the trigger of mushroom plus exercise (exposures for mushrooms plus exercise about at least twice a month), but no anaphylaxis within this time, and after stopping dupilumab and avoiding mushrooms (Figure 1). The diagnosis standard of anaphylaxis is based on the WAO guideline.6 The patient returned to normal exercise (running 1-2 km, soccer, etc.) with an improvement in quality of life and no adverse reactions occurred.Total IgE and specific IgE decreased significantly...
- Open Access
- 18 August 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (22) , 2738-2740
Characteristics of cow's milk allergy and sensitization in Chinese patients
- 18 August 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (22) , 2738-2740
Open AccessCharacteristics of cow's milk allergy and sensitization in Chinese patients
- Open Access
- 28 July 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 913424
Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study
Background: Allergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose. Seasonal ARC (SARC) is usually induced by seasonal allergens and often occurs at specific times during the year. Traditional treatments of SARC include nasal corticosteroids, antihistamines, and mast cell membrane stabilizers. Biological agents such as omalizumab have also been proved effective in the treatment of SARC.Objectives: We aim to certify the preventative efficacy of omalizumab for SARC and explore its influence factors.Methods: Medical records of 64 SARC patients were retrospectively analyzed, and generalized linear models were used to analyze influence factors of efficacy of omalizumab.Results: Compared with forepassed pollen season without omalizumab treatment, the combined symptom and medication score (CSMS) of ARC with pre-seasonal omalizumab was significantly lower (with omalizumab: 0.67[0.00,1.83], without omalizumab: 4.00[2.83,4.96], p0.05).Conclusion: Pre-seasonal omalizumab treatment could significantly relieve SARC related symptoms and reduce medication use. This preventative efficacy would not be influenced by the dosage and number of injections of omalizumab. A single dose of 150mg omalizumab could achieve a satisfactory outcome.
- 28 July 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 913424
Open AccessPrevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study
Background: Allergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose. Seasonal ARC (SARC) is usually induced by seasonal allergens and often occurs at specific times during the year. Traditional treatments of SARC include nasal corticosteroids, antihistamines, and mast cell membrane stabilizers. Biological agents such as omalizumab have also been proved effective in the treatment of SARC.Objectives: We aim to certify the preventative efficacy of omalizumab for SARC and explore its influence factors.Methods: Medical records of 64 SARC patients were retrospectively analyzed, and generalized linear models were used to analyze influence factors of efficacy of omalizumab.Results: Compared with forepassed pollen season without omalizumab treatment, the combined symptom and medication score (CSMS) of ARC with pre-seasonal omalizumab was significantly lower (with omalizumab: 0.67[0.00,1.83], without omalizumab: 4.00[2.83,4.96], p0.05).Conclusion: Pre-seasonal omalizumab treatment could significantly relieve SARC related symptoms and reduce medication use. This preventative efficacy would not be influenced by the dosage and number of injections of omalizumab. A single dose of 150mg omalizumab could achieve a satisfactory outcome.
- Open Access
- 23 July 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (21) , 2602-2604
A novel treatment workflow of idiopathic hypereosinophilic syndrome: a single-center retrospective cohort study
- 23 July 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (21) , 2602-2604
Open AccessA novel treatment workflow of idiopathic hypereosinophilic syndrome: a single-center retrospective cohort study
- Open Access
- 22 December 2021
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (2) , 219-221
High house dust mite serum-specific immunoglobulin E indicates a high 5-year rhinitis-asthma conversion rate: a cross-sectional study
- 22 December 2021
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (2) , 219-221
Open AccessHigh house dust mite serum-specific immunoglobulin E indicates a high 5-year rhinitis-asthma conversion rate: a cross-sectional study